Terms: = Ovarian cancer AND GPC3, OCI-5, 2719, ENSG00000147257, SGBS, SGB, DGSX, SDYS, P51654, AC002420_1, SGBS1 AND Treatment
12 results:
1. Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.
Cheng F; Hansson VC; Georgolopoulos G; Mani K
Oncotarget; 2023 Mar; 14():219-235. PubMed ID: 36944188
[TBL] [Abstract] [Full Text] [Related]
2. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
[TBL] [Abstract] [Full Text] [Related]
3. Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams SF; Grimm AJ; Chiang CL; Mookerjee A; Flies D; Jean S; McCann GA; Michaux J; Pak H; Huber F; Neal C; Dangaj D; Bassani-Sternberg M; Rusakiewicz S; Facciabene A; Coukos G; Gimotty PA; Kandalaft LE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817208
[TBL] [Abstract] [Full Text] [Related]
4. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract] [Full Text] [Related]
5. [Pathologic features on gonadal changes of sexual developmental disorders in children].
Yi P; Niu HL; Gao Q; Wang FH; Jia W; Chen ZR; Xia JQ; Li LP; Cao Y; Zeng RX
Zhonghua Bing Li Xue Za Zhi; 2018 Jul; 47(7):531-535. PubMed ID: 29996319
[No Abstract] [Full Text] [Related]
6. Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review.
Chao WT; Liu CH; Lai CR; Chen YJ; Chuang CM; Wang PH
J Ovarian Res; 2018 Jun; 11(1):52. PubMed ID: 29933751
[TBL] [Abstract] [Full Text] [Related]
7. [cancer peptide vaccine targeted glypican-3 antigen].
Nakatsura T
Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
[TBL] [Abstract] [Full Text] [Related]
8. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
Suzuki S; Shibata K; Kikkawa F; Nakatsura T
Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
[TBL] [Abstract] [Full Text] [Related]
9. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract] [Full Text] [Related]
10. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.
Varma RR; Hector SM; Clark K; Greco WR; Hawthorn L; Pendyala L
Oncol Rep; 2005 Oct; 14(4):925-32. PubMed ID: 16142353
[TBL] [Abstract] [Full Text] [Related]
11. [Surgical treatment of ovarian malignant tumors metastasized to the gastro-intestinal tract: a report of 131 cases].
Peng Z; Pan X; Liu H
Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):142-4. PubMed ID: 11776859
[TBL] [Abstract] [Full Text] [Related]
12. Frequent silencing of the gpc3 gene in ovarian cancer cell lines.
Lin H; Huber R; Schlessinger D; Morin PJ
Cancer Res; 1999 Feb; 59(4):807-10. PubMed ID: 10029067
[TBL] [Abstract] [Full Text] [Related]
